^
Association details:
| Biomarker: | CUX1-ALK fusion |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Xalkori (crizotinib) (ALK inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
CMTR1-ALK: an ALK fusion in a patient with no response to ALK inhibitor crizotinib
Excerpt:
After detection of the CUX1-ALK fusion gene...the patient showed a superior response to crizotinib, with a progression-free survival of 20 months....This study provides the novel finding of a CUX1-ALK fusion gene from a patient with NSCLC that could provide personalized treatment solutions for the maximum benefit to patients with NSCLC.
DOI:
10.1080/15384047.2018.1480282
